jounce
therapeutics
announces
update
vopratelimab
program
enrollment
emerge
trial
vopratelimab
combination
ipilimumab
based
interim
first
patient
dosed
select
trial
vopratelimab
combination
immunotherapy
naïve
host
conference
call
webcast
today
cambridge
globe
newswire
jounce
therapeutics
nasdaq
jnce
company
focused
discovery
development
novel
cancer
immunotherapies
predictive
biomarkers
today
provided
update
vopratelimab
vopra
program
intent
emerge
phase
trial
induce
icos
hi
cells
ipilimumab
administer
vopra
goal
increasing
proliferation
expansion
icos
hi
cells
associated
durable
clinical
benefit
iconic
trial
vopra
alone
combination
inhibitor
early
evaluation
data
emerge
trial
vopra
combination
ipilimumab
l
inhibitor
experienced
cell
lung
cancer
nsclc
patients
indicates
trial
meet
interim
criteria
continuation
enrollment
therefore
emerge
trial
expanded
company
also
announced
first
patient
dosed
select
phase
trial
supporting
vopra
potential
combination
immunotherapy
naïve
nsclc
patients
disappointed
early
look
emerge
data
indicates
meet
interim
criteria
continued
enrollment
said
beth
trehu
chief
medical
officer
jounce
therapeutics
less
emerge
patients
emergence
icos
hi
cells
ipilimumab
treatment
indicating
cell
activation
inhibitors
may
impaired
l
inhibitor
resistant
patients
patients
progressed
inhibitor
therapies
represent
large
growing
unmet
need
new
therapeutic
mechanisms
may
needed
effectively
treat
patients
would
like
thank
patients
investigators
study
teams
participation
emerge
l
experienced
resistant
population
continues
prove
difficult
treat
bring
necessary
benefit
patients
becoming
clearer
novel
approaches
beyond
cells
may
needed
part
solution
said
richard
murray
chief
executive
officer
president
jounce
therapeutics
pipeline
beyond
vopra
focused
novel
approaches
believe
existing
programs
particularly
lead
macrophage
program
targeting
programs
discovery
platform
poised
make
meaningful
contributions
l
naïve
resistant
emerge
enrollment
dosing
safety
patients
enrolled
evaluable
based
criteria
required
least
one
dose
drug
least
one
ct
scan
response
assessment
clinical
progression
without
vopra
continued
safe
combination
ipilimumab
well
tolerated
type
frequency
adverse
events
similar
seen
ipilimumab
summary
emerge
preliminary
efficacy
data
mg
kg
vopratelimab
mg
kg
ipilimumab
mg
kg
vopratelimab
mg
kg
ipilimumab
mg
kg
vopratelimab
mg
kg
ipilimumab
doses
combined
evaluable
patients
n
patients
tumor
reduction
n
confirmed
orr
n
os
median
ci
ne
ne
ne
ne
ne
ne
patients
remaining
study
dose
due
dosing
error
single
study
site
confidence
interval
estimable
ipilimumab
dosed
maximum
doses
data
october
data
doses
combined
without
including
subjects
dosed
mg
kg
meet
criteria
continuation
enrollment
trial
tumor
reduction
patients
one
confirmed
recist
response
mg
kg
cohort
patients
tumor
reduction
confirmed
overall
response
rate
orr
median
overall
survival
os
dose
groups
combined
months
reached
mg
kg
cohorts
nine
patients
remain
study
including
four
patients
continuing
benefit
vopra
alone
completion
four
ipilimumab
doses
biomarker
analysis
yet
complete
emerge
interim
analysis
clinical
criteria
expand
trial
tumor
reduction
patients
median
overall
survival
tracking
months
overall
response
rate
interim
analysis
criteria
selected
provide
preliminary
evidence
combination
vopra
ipilimumab
could
potentially
superior
docetaxel
randomized
phase
trial
overall
survival
endpoint
early
data
evaluation
indicates
across
emerge
doses
interim
criteria
met
emerge
expanded
beyond
current
enrollment
select
select
emerge
developed
address
distinct
hypotheses
potential
vopra
icos
hi
cells
improve
patient
outcomes
trials
also
addressing
different
patient
populations
l
inhibitor
resistant
versus
l
inhibitor
naïve
biomarker
selected
randomized
phase
select
trial
vopra
combination
jounce
inhibitor
began
enrollment
october
trial
compares
vopra
plus
alone
immunotherapy
naïve
nsclc
patients
tisvopra
predictive
biomarker
select
enroll
approximately
patients
tisvopra
gene
rna
tumor
inflammation
signature
optimized
predict
emergence
icos
hi
cells
associated
clinical
benefit
select
powered
demonstrate
statistical
superiority
combination
vopratelimab
plus
compared
alone
preliminary
efficacy
data
select
trial
expected
conference
call
webcast
information
jounce
therapeutics
host
conference
call
webcast
today
et
access
conference
call
please
dial
domestic
international
refer
conference
id
webcast
accessed
events
presentations
investors
media
section
jounce
website
webcast
archived
made
available
replay
jounce
website
approximately
two
hours
call
available
days
vopratelimab
vopratelimab
monoclonal
antibody
binds
activates
icos
inducible
cell
protein
surface
certain
cells
commonly
found
many
solid
tumors
vopratelimab
currently
assessed
select
phase
clinical
trial
combination
jounce
internal
investigational
inhibitor
compared
alone
select
trial
currently
enrolling
approximately
immunotherapy
naïve
nsclc
patients
tisvopra
predictive
biomarker
gene
rna
tumor
inflammation
signature
predicted
emergence
icos
hi
cells
clinical
benefit
iconic
trial
vopratelimab
alone
combination
inhibitor
select
powered
demonstrate
statistical
superiority
combination
vopratelimab
plus
compared
jounce
therapeutics
jounce
therapeutics
immunotherapy
company
dedicated
transforming
treatment
cancer
developing
therapies
enable
immune
system
attack
tumors
provide
benefits
patients
approach
jounce
currently
multiple
development
stage
programs
ongoing
simultaneously
advancing
additional
assets
robust
discovery
engine
based
translational
science
platform
jounce
advanced
product
candidate
vopratelimab
monoclonal
antibody
binds
activates
icos
currently
studied
select
phase
trial
inhibitor
intended
combination
use
select
trial
jounce
broader
pipeline
jounce
next
development
stage
product
candidate
receptor
antagonist
shown
reprogram
tumor
associated
macrophages
state
phase
trial
evaluating
planned
begin
enrollment
fourth
quarter
additionally
jounce
exclusively
licensed
worldwide
rights
monoclonal
antibody
targeting
designed
selectively
deplete
regulatory
cells
tumor
microenvironment
gilead
sciences
information
please
visit
cautionary
note
regarding
statements
various
statements
release
concerning
jounce
future
expectations
plans
including
without
limitation
jounce
expectations
regarding
timing
initiation
progress
results
release
data
clinical
trials
jounce
product
candidates
including
vopratelimab
may
constitute
statements
purposes
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
subject
substantial
risks
uncertainties
assumptions
place
reliance
statements
often
include
words
expect
look
forward
similar
terms
variations
terms
negative
terms
although
jounce
believes
expectations
reflected
statements
reasonable
jounce
guarantee
outcomes
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
without
limitation
risks
pandemic
may
disrupt
jounce
business
global
healthcare
system
severely
anticipated
may
effect
delaying
enrollment
completion
jounce
clinical
trials
delaying
timelines
data
disclosures
regulatory
submissions
product
candidates
jounce
ability
successfully
demonstrate
efficacy
safety
product
candidates
jounce
ability
successfully
manage
clinical
trials
development
plans
product
candidates
companion
complementary
diagnostics
management
jounce
supply
chain
delivery
drug
product
materials
use
clinical
trials
actions
regulatory
agencies
may
affect
initiation
timing
progress
preclinical
studies
clinical
trials
jounce
product
candidates
risks
fully
discussed
section
entitled
risk
factors
jounce
recent
annual
report
form
filed
securities
exchange
commission
well
discussions
potential
risks
uncertainties
important
factors
jounce
subsequent
filings
securities
exchange
commission
statements
speak
date
made
jounce
undertakes
obligation
update
revise
publicly
statements
whether
result
new
information
future
events
otherwise
investor
media
contacts
mark
yore
myore
malin
deon
mdeon
